-
International Journal of Women's Health
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis
Original Research
(575) Views (203) Full article downloads
Authors: Maia Jr H, Haddad C, Casoy J
Published Date February 2012
Volume 2012:4 Pages 61 - 65
DOI: http://dx.doi.org/10.2147/IJWH.S29154
Hugo Maia Jr1,2, Clarice Haddad1,2, Julio Casoy11CEPARH, 2Itaigara Memorial Day Hospital, Salvador, Bahia, Brazil
Objective: To investigate whether aromatase expression in the eutopic endometrium correlates with the presence and severity of endometriosis in patients with infertility and/or dysmenorrhea undergoing laparoscopy and hysteroscopy.
Patients: The study involved 106 patients of reproductive age with symptoms of dysmenorrhea and infertility. Sixteen endometriosis-free asymptomatic patients were used as a control group.
Methods: Concomitant laparoscopy and hysteroscopy was carried out in all cases. An endometrial biopsy was taken to determine aromatase p450 expression by immunohistochemistry. Endometriosis was staged according to the American Society of Reproductive Medicine classification.
Results: Endometriosis was diagnosed by laparoscopy in 92/106 symptomatic patients. In this group, aromatase expression was detected in the eutopic endometrium of 66/92 patients with endometriosis (72%) and in 13/14 (95%) patients in the symptomatic, endometriosis-free group (P = 0.09). Aromatase expression was not detected in any patients from the control group. In the endometriosis group, aromatase expression was detected in the eutopic endometrium of 28/45 patients (62%) with American Society of Reproductive Medicine classification stage 1 of the disease, in 11/14 patients (78%) with stage II, 14/20 patients (70%) with stage III, and in 12/13 patients (92%) with stage IV; however, the difference was only statistically significant between stages I and IV (P = 0.04).
Conclusion: Aromatase expression in the endometrium was associated with the presence of dysmenorrhea and infertility irrespective of the presence of endometriosis. When endometriosis was present, however, there was a tendency for aromatase expression to be positively correlated with dysmenorrhea severity.
Keywords: aromatase, endometrium, endometriosis, Cox-2, dysmenorrhea
Other articles by Dr Hugo Maia Jr.
Readers of this article also read:
Use of capecitabine in management of early colon cancer
The effects of acupressure on severity of primary dysmenorrhea
Cervical cancer screening in primary health care setting in Sudan: a comparative study of visual inspection with acetic acid and Pap smear
Psychiatric morbidity among Egyptian breast cancer patients and their partners and its impact on surgical decision-making
Remote prognosis after primary cesarean delivery: the association of VBACs and recurrent cesarean deliveries with maternal morbidity
Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection
Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma
Critical evaluation of the efficacy and tolerability of azilsartan
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions
- Tinidazole in the treatment of bacterial vaginosis
- Diagnosis and management of pre-eclampsia: an update
- Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy




